科研动态PubMed 摘要

生物可吸收血管支架与当代药物洗脱支架治疗冠状动脉疾病的有效性和安全性:一项系统评价、荟萃分析和试验序贯分析。

PubMed 学科轮询 · 2026-10-20

完整摘要 · 中文译文

背景:生物可吸收血管支架(BVS)的研发旨在解决与永久性金属药物洗脱支架(DES)相关的一些局限性,但这些支架的比较安全性和有效性仍不确定。 方法:我们对比较BVS与当代DES在冠状动脉疾病患者中应用的随机研究和观察性研究进行了系统综述和荟萃分析。主要结局为1年时的复合临床终点。次要结局包括死亡率、心肌梗死(MI)、血运重建、血栓形成和血管造影指标。2年、3年和5年时的结局分别进行分析。采用试验序贯分析(TSA)评估主要结局证据的稳健性。 结果:共纳入51项研究(69篇报告)。在1年时,BVS与DES相比复合临床终点风险更高(风险比(RR)1.11,95%置信区间(CI 1.00-1.22)),主要由MI、靶病变血运重建和血栓形成风险增加所驱动。相比之下,全因死亡率和心源性死亡率在两组间无显著差异。TSA显示,尽管累积Z曲线达到了所需信息量,但Z值未跨越试验序贯监测边界,表明主要终点的证据仍无定论。在中长期随访期间,BVS仍与更高的缺血事件和重复血运重建风险相关,而无生存获益。血管造影分析显示晚期管腔丢失更大 s、更小的最小管腔直径以及更大的直径狭窄率与BVS相关。 结论:与当代药物洗脱支架(DES)相比,BVS似乎带来更高的缺血风险,且无长期生存获益。当代DES仍是首选的再血管化策略。

完整摘要 · 英文原文

BACKGROUND: Bioresorbable vascular scaffolds (BVS) were developed to address some limitations associated with permanent metallic drug-eluting stents (DES), but the comparative safety and efficacy of these scaffolds remain uncertain. METHODS: We conducted a systematic review and meta-analysis of randomized and observational studies comparing BVS with contemporary DES in patients with coronary artery disease. The primary outcome was the composite clinical endpoint at 1-year. Secondary outcomes included mortality, myocardial infarction (MI), revascularization, thrombosis, and angiographic measures. Outcomes at 2, 3, and 5 years were analyzed separately. Trial sequential analysis (TSA) was used to assess the robustness of the evidence for the primary outcome. RESULTS: A total of 51 studies (69 reports) were included. At 1 year, BVS was associated with a higher risk of the composite clinical endpoint than DES (risk ratio (RR) 1.11, 95% confidence interval (CI 1.00-1.22)), mainly driven by increased risks of MI, target lesion revascularization, and thrombosis. In contrast, all-cause and cardiac mortality did not differ significantly between groups. TSA showed that although the cumulative Z-curve reached the required information size, the Z-score did not cross the trial sequential monitoring boundary, indicating that the evidence for the primary endpoint remained inconclusive. During mid- and long-term follow-up, BVS remained associated with higher risks of ischemic events and repeat revascularization, without a survival benefit. Angiographic analyses showed greater late lumen loss, smaller minimal lumen diameter, and greater diameter stenosis with BVS. CONCLUSIONS: Compared with contemporary DES, BVS appears to confer a higher ischemic risk without a long-term mortality benefit. Contemporary DES remains the preferred revascularization strategy.

English
Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界